Gyre Therapeutics (NASDAQ:GYRE) reported a year of strategic transformation and steady financial growth for the full year 2025, posting total revenue of $116.6 million, a 10.2% increase compared to the prior year.
The company ended the period with a solid liquidity position, reporting $75.9 million in cash and deposits as of December 31, 2025.
The centerpiece of the company's forward-looking strategy is a definitive agreement to acquire Cullgen for approximately $300 million.
The acquisition is expected to significantly broaden Gyre’s portfolio by integrating Cullgen’s targeted protein degradation platform, positioning the combined entity to address a wider range of unmet needs in fibrosis and inflammatory diseases.
On the clinical front, Gyre is nearing critical regulatory and data milestones.
The company confirmed it is on track to submit a New Drug Application (NDA) for Hydronidone for conditional approval in China during the first half of 2026.
Additionally, the firm has completed enrollment for its 52-week Phase 3 clinical trial of pirfenidone, which includes 272 patients, further strengthening its late-stage pipeline in the respiratory and fibrotic space.
Looking ahead, management issued 2026 revenue guidance in the range of $100.5 million to $111 million.